Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Azetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azetidine SCHEMBL10752541 | 1.00 | — | — | |
| Azetidine SCHEMBL27991211 | 1.00 | — | — | |
| Azetidine SCHEMBL12502 | 0.93 | — | — | |
| Azetidine SCHEMBL28328821 | 0.93 | — | — | |
| Pyrrolidine SCHEMBL3853339 | 0.88 | ALDH1A1 (0.80) | — | |
| Pyrrolidine SCHEMBL724812 | 0.88 | — | — | |
| Pyrrolidine SCHEMBL996579 | 0.88 | ALDH1A1 (0.80) | — | |
| Pyrrolidine SCHEMBL28547040 | 0.88 | ALDH1A1 (0.80) | — | |
| Azetidine SCHEMBL23754598 | 0.86 | — | — | |
| Azetidine SCHEMBL8051426 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993608-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4308581-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117379428-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-116981679-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112638916-B | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11744844-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234960-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-07-27 | — | — | US | disclosed |
| US-11634426-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115960355-A | Method for preparing sulfur-containing polymer based on isomerization-driven irreversible ring-opening polymerization | 中国科学院上海有机化学研究所 | 2023-04-14 | — | — | CN | disclosed |
| EP-4155310-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-2032566-A4 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD (CA) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-07-02 | — | — | US | disclosed |
| EP-2032566-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143823-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | disclosed |
| EP-0788498-B1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2001-08-16 | — | — | EP | disclosed |
| CN-1068325-C | phenyl oxazolidinone antibacterial agents | PHARMACIA & UPJOHN CO LLC (US) | 2001-07-11 | — | — | CN | disclosed |
| US-5883093-A | TREATING MICROBIAL INFECTIONS IN WARM BLOODED ANIMALS, INCLUDING HUMANS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| CN-1162312-A | Phenyloxazolidinone antimicrobials | PHARMACIA & UPJOHN CO LLC (US) | 1997-10-15 | — | — | CN | disclosed |
| EP-0788498-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013502-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |